Wealth Awesome
TSX open
Loading markets…
Interactive Brokers: options trading made simple with the IBKR Options Wizard.
Stocks/TSX/APS

Aptose Biosciences Inc (APS : TSX)

$2.40CAD+0.00 (%)Close of 2026-07-03

Common Stock

Follow APS

APS

Aptose Biosciences Inc

Source:WealthAwesomeWealthAwesome
↑ $0.02 (0.84%)
30 day period
$2.12$2.26$2.40May 22Jun 12Jul 3

Performance

1 Day

+0.00%

1 Week

+0.00%

1 Month

+0.00%

YTD

+18.81%

The Tuesday Stock Pick · free, every tuesday morning. One Canadian stock and the case for it.

Key Statistics

Market Cap

$6.13M

52W High

$2.59

52W Low

$1.41

P/E Ratio

-

50 Day MA

$2.25

200 Day MA

$2.14

Beta

0.34

Dividend Yield

-

Performance history

APS returns since 2023

Aptose Biosciences Inc has traded since Nov 2023 in our data, with 1 up year out of 2 full calendar years. Its deepest fall was −95.1% (Nov 2023 to Feb 2025).

1 year / yr

+101.7%

3 years / yr

—

5 years / yr

—

10 years / yr

—

Calendar-year returns

  • 2023*−21.5%
  • 2024−90.1%
  • 2025+542.4%
  • 2026*+13.2%

* Partial year (first year of data, or year to date).

$10,000 invested in APS

  • 1 year ago$20,168
  • 2023 (start of our data)$5,621
Best year
2025: +542.4%
Worst year
2024: −90.1%
All-time high in our data
$6 on Mar 20, 2025 · now −57.6%

Total-return basis using adjusted daily closes from the Toronto Stock Exchange and TSX Venture (dividends and splits folded in), Nov 2023 to Jul 2026. Past returns do not predict future ones.

Awesome Portfolio™

Looking past APS? Our 10 best Canadian stocks, in one list.

14.8% a year since 2017 against 9.7% for the S&P/TSX Composite (+5.0 points a year). Reviewed every month.

See the portfolio →

Technical Indicators

Price vs 50-Day SMA

↑Above 50 SMA

Price vs 200-Day SMA

↑Above 200 SMA

Recent Price History

DateOpenHighLowCloseAdj CloseVolume
7/3/2026$2.40$2.40$2.40$2.40$2.402,945
7/2/2026$2.40$2.41$2.40$2.40$2.4032,232
6/30/2026$2.13$2.14$2.13$2.14$2.14200
6/29/2026$2.25$2.25$2.25$2.25$2.250
6/26/2026$2.20$2.25$2.20$2.25$2.25305
6/25/2026$2.20$2.20$2.20$2.20$2.20100
6/24/2026$2.20$2.20$2.20$2.20$2.203,010
6/23/2026$2.12$2.13$2.12$2.13$2.131,100
6/22/2026$2.08$2.20$2.08$2.12$2.121,196
6/19/2026$2.20$2.20$2.20$2.20$2.200

Analyst Price Targets

Based on analyst covering APS · as of Sep 17, 2026

📉

Wall Street analysts forecast APS stock price to fall 1.7% over the next 12 months.

Consensus

Neutral

Based on avg. target vs last close (formal rating unavailable for Canadian listings)

Avg. Target

C$2.36

-1.7% Upside

Current Price

C$2.40

Last close

Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on APS's historical volatility

HistoricalForecast68%95%
C$1.24C$1.92C$2.60C$3.28C$3.96C$4.64TodayFeb 24Apr 30Jul 3Aug 15Sep 28Nov 10

30-Day Vol

52.7%

Annualized

90-Day Vol

48.9%

Annualized

Trend (90d)

-0.0%

Annualized drift

90d Mean

C$2.40

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$2.40C$2.00 – C$2.88
60 trading daysC$2.40C$1.86 – C$3.10
90 trading daysC$2.40C$1.75 – C$3.29

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

About Aptose Biosciences Inc

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes. It has license agreements with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Financials

Revenue (TTM)
$0
EBITDA
$-26.42M
Profit Margin
0.00%
ROE (TTM)
-694.13%
EPS (Diluted)
-14.78
Book Value
-19.30

Classification

Sector
Health Care
Industry
Biotechnology
Group
Pharmaceuticals, Biotechnology & Life Sciences

Free newsletter

The Tuesday Stock Pick

Tuesday morning

One Canadian stock and the case for it

  • The name with the biggest gap to analyst targets
  • The chart, insider buying and what is driving it
  • A plain-English bottom line, no hype

Free. One email a week. Unsubscribe any time.

Common Questions About APS

Market movers

Recent TSX movers

Top 1-day gainers — updated from our Canadian movers feed.

All movers →
TickerNamePrice1D
HWOHigh Arctic Energy Services Inc.$1.74+29.85%
AAVAdvantage Oil & Gas Ltd.$13.45+23.74%
LUCLucara Diamond Corp$0.13+13.64%
TTelus Corp$13.70+12.85%
FRXFennec Pharmaceuticals Inc$18.35+10.81%
KELKelt Exploration Ltd.$12.72+10.70%
NVONovo Resources Corp$0.07+8.33%
ELOEloro Resources Ltd.$1.23+7.89%

Free with a Wealth Awesome account

Keep analysing APS, free

  • Every WA Score, ranking and table
  • Insider track records and SEDI filings
  • Earnings history and analyst targets for every stock

Email only, no password, no card. Already a member? Use the same button to sign in.